London (PRWEB UK) 30 January 2014
Controlled release remains one of the most important innovate areas in pharma, with revenues set to dramatically increase to 2020. Recent advances in drug delivery systems have created the perfect mix for opportunities in the field.
This meeting will continue in a long tradition of critically acclaimed speakers who are pioneers in their field. This event offers you a unique opportunity to keep up to date with the latest in technologies and methods such as the diffusion of nanomaterials through biological and non-biological gels.
Key presentations in this conference include:
-Setting Specifications for Controlled Release Products: A Statistically Based Approach
David Elder, Externalisation Director, GlaxoSmithKline Research & Development
-Oral drug delivery technology- the challenges an industrial and academic perspective
Luigi Martini, Professor of Pharmaceutical Innovation, Kings College London
-Peptide Delivery: What Is the Present Status and What Does the Future Hold?
Joel Richard, Vice President Peptides , IPSEN
-Creating extended half-life peptide therapeutics using AlbudAbsTM
Oliver Schon, Group Leader, NBE Profiling & Analysis, Biopharm Innovation, BIOpharm, GlaxoSmithKline
-Development and characterization of parenteral in situ gelling chitosan/glucose-1-phosphate depot systems
Stephanie Supper, Senior Scientist, Novartis Pharmaceuticals
Companies and organisations that have previously attended this conference include:
For those who are interested in participating in this event there is currently an early bird discount of £100 for registrations until the 31st of January. For more information visit the website or contact Fateja Begum on +44 (0) 20 7827 6184 or email fbegum(at)smi-online(dot)co(dot)uk.